SS-31 50mg (Without mannitol)

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.


SS-31 Peptide Structure
Sequence: D-Arg-Tyr(2,6-diMe)-Lys-Phe
Molecular Formula: C32H49N₂O5
Molecular Weight: 639.8 g/mol
PubChem CID: 11764719
CAS Number: 736992-21-5
Synonyms: elamipretide, MTP-131, Bendavia

Image Checkout
Guaranteed Checkout
Want a discount? Become a member!

SS-31, also known as elamipretide, constitutes a small, aromatic peptide recognized for its remarkable ability to effortlessly traverse cell and organelle membranes. Its proposed mechanism involves interference with the generation of reactive oxygen species (ROS or free radicals) while fostering cellular energy production. This is achieved by stabilizing the enzyme cardiolipin situated within mitochondria, a vital element of the inner mitochondrial membrane essential for the electron transport chain—an integral machinery responsible for producing the majority of cellular energy.

Dysfunction in cardiolipin has been implicated in the pathology of various diseases, spanning Alzheimer’s disease, Parkinson’s disease, nonalcoholic fatty liver disease, diabetes, heart failure, HIV, cancer, chronic fatigue syndrome, among others. Furthermore, cardiolipin’s role is pivotal in mitochondrial myopathy—a group of neuromuscular disorders resulting from mitochondrial damage. This condition encompasses a spectrum from muscle weakness and exercise intolerance to heart failure, seizures, and dementia.

Remarkably, SS-31 holds the distinction of being the initial peptide to undergo clinical trials as a potential treatment for mitochondrial myopathy.